oxybutynin has been researched along with Cystitis in 7 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To clarify the basic mechanism involved in the pathophysiology of cystitis by characterizing the urodynamic parameters, pharmacologically relevant (muscarinic and purinergic) receptors, and the in vivo release of adenosine triphosphate (ATP) in the bladder of hydrochloric acid (HCl)-treated rats." | 7.76 | Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. ( Fujino, T; Kageyama, A; Nozawa, Y; Yamada, S; Yoshida, A, 2010) |
| " In this study, we investigated the effect of the recently developed P2X3 and P2X2/3 receptor antagonist A-317491 on cyclophosphamide (CYP)-induced cystitis to determine whether a P2X receptor antagonist could be beneficial for the treatment of bladder overactivity induced by CYP." | 7.74 | Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. ( Ikeda, M; Ito, K; Iwami, A; Katsura, H, 2008) |
| "We investigated the effects of AH-9700 (1-[2-(3,4-dihydro-6,7-dimethyl-2-naphthalenyl)ethyl] pyrrolidine fumarate; a novel sigma receptor ligand), (+)-pentazocine and 1,3-di-o-tolylguanidine (DTG) (two typical sigma receptor ligands), and oxybutynin (a currently used anti-pollakiuria drug) on cystometrograms in anesthetized rats with 30% acetone-induced cystitis." | 7.71 | Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis. ( Ishii, D; Kawashima, K; Oka, M; Shimizu, I, 2001) |
| "To clarify the basic mechanism involved in the pathophysiology of cystitis by characterizing the urodynamic parameters, pharmacologically relevant (muscarinic and purinergic) receptors, and the in vivo release of adenosine triphosphate (ATP) in the bladder of hydrochloric acid (HCl)-treated rats." | 3.76 | Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. ( Fujino, T; Kageyama, A; Nozawa, Y; Yamada, S; Yoshida, A, 2010) |
| " In this study, we investigated the effect of the recently developed P2X3 and P2X2/3 receptor antagonist A-317491 on cyclophosphamide (CYP)-induced cystitis to determine whether a P2X receptor antagonist could be beneficial for the treatment of bladder overactivity induced by CYP." | 3.74 | Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. ( Ikeda, M; Ito, K; Iwami, A; Katsura, H, 2008) |
| "We investigated the effects of AH-9700 (1-[2-(3,4-dihydro-6,7-dimethyl-2-naphthalenyl)ethyl] pyrrolidine fumarate; a novel sigma receptor ligand), (+)-pentazocine and 1,3-di-o-tolylguanidine (DTG) (two typical sigma receptor ligands), and oxybutynin (a currently used anti-pollakiuria drug) on cystometrograms in anesthetized rats with 30% acetone-induced cystitis." | 3.71 | Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis. ( Ishii, D; Kawashima, K; Oka, M; Shimizu, I, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ness, TJ | 1 |
| McNaught, J | 1 |
| Clodfelder-Miller, B | 1 |
| Su, X | 1 |
| Yoshida, A | 1 |
| Kageyama, A | 1 |
| Fujino, T | 1 |
| Nozawa, Y | 1 |
| Yamada, S | 1 |
| Zama, D | 1 |
| Masetti, R | 1 |
| Vendemini, F | 1 |
| Di Donato, F | 1 |
| Morelli, A | 1 |
| Prete, A | 1 |
| Pession, A | 1 |
| Ito, K | 1 |
| Iwami, A | 1 |
| Katsura, H | 1 |
| Ikeda, M | 1 |
| Landau, EH | 1 |
| Fung, LC | 1 |
| Thorner, PS | 1 |
| Mittelman, MW | 1 |
| Jayanthi, VR | 1 |
| Churchill, BM | 1 |
| McLorie, GA | 1 |
| Steckler, RE | 1 |
| Khoury, AE | 1 |
| Shimizu, I | 1 |
| Kawashima, K | 1 |
| Ishii, D | 1 |
| Oka, M | 1 |
| Renshaw, DC | 1 |
7 other studies available for oxybutynin and Cystitis
| Article | Year |
|---|---|
Medications used to treat bladder disorders may alter effects of neuromodulation.
Topics: Acetanilides; Animals; Cystitis; Electric Stimulation Therapy; Female; Mandelic Acids; Muscle Contra | 2020 |
Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
Topics: Adenosine Triphosphate; Animals; Benzhydryl Compounds; Benzofurans; Cresols; Cystitis; Disease Model | 2010 |
Clinical effectiveness of early treatment with hyperbaric oxygen therapy for severe late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in pediatric patients.
Topics: Child; Cystitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Hyperbaric Oxy | 2013 |
Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats.
Topics: Animals; Cyclophosphamide; Cystitis; Disease Models, Animal; Dose-Response Relationship, Drug; Femal | 2008 |
Histologic studies of intravesical oxybutynin in the rabbit.
Topics: Administration, Intravesical; Animals; Cystitis; Female; Mandelic Acids; Parasympatholytics; Powders | 1995 |
Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis.
Topics: Acetone; Anesthesia; Animals; Cystitis; Disease Models, Animal; Fumarates; Guanidines; Male; Mandeli | 2001 |
Desipramine for interstitial cystitis.
Topics: Adult; Cystitis; Depression; Desipramine; Female; Humans; Mandelic Acids | 1988 |